Lilly reports positive data for Omvoh versus Stelara in Crohn’s
by
Contributor since / Followers
Contributor since / Followers
1 month ago
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) reported positive one-year data from a Phase 3 study that compared its drug Omvoh to Johnson & Johnson’s (JNJ) Stelara in the treatment of Crohn’s disease.
- Lilly said the study, called VIVID-1, showed more patients achieved histologic response at Week 52 on Omvoh, also known as mirikizumab, versus Stelara, also known as ustekinumab, in patients with moderately to severely active Crohn’s disease, according to a statement.
- Omvah is already approved for the treatment of moderately to severely active ulcerative colitis in adults. Lilly has submitted marketing authorization applications for the drug in the treatment of Crohn’s disease to regulators worldwide, including the U.S., Europe, Japan and China, the company added.
- Stelara, which is marketed by Johnson & Johnson (JNJ), is approved for several indications, including ulcerative colitis, Crohn’s disease, plaque psoriasis and psoriatic arthritis.